Vident Investment Advisory’s Inovio Pharmaceuticals INO Stock Holding History

Vident Investment Advisory’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-33,195	Closed	-$1.96M	–	939
2018 Q1	$1.96M	Buy	33,195 +8,886	+37%	+$481K	0.08%	312
2017 Q4	$1.21M	Buy	24,309 +11,860	+95%	+$735K	0.05%	353
2017 Q3	$947K	Buy	12,449 +377	+3%	+$28.1K	0.05%	371
2017 Q2	$1.14M	Buy	12,072 +1,457	+14%	+$125K	0.09%	310
2017 Q1	$843K	Buy	10,615 +1,769	+20%	+$141K	0.08%	321
2016 Q4	$737K	Buy	8,846 +3,564	+67%	+$322K	0.09%	307
2016 Q3	$591K	Hold	5,282	–	–	0.08%	327
2016 Q2	$586K	Sell	5,282 -12,300	-70%	-$1.49M	0.08%	359
2016 Q1	$1.84K	Buy	17,582 +8,205	+88%	+$633K	0.11%	315
2015 Q4	$756K	Buy	+9,377	New	+$747K	0.1%	341

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vident Investment Advisory's INO Position: Q2 2018 in Review

Vident Investment Advisory sold out of Inovio Pharmaceuticals (INO) in Q2 2018, closing a stake of 33,195 shares — an estimated $1.96M sold.

Vident Investment Advisory first reported a position in INO in Q4 2015 and held it in 10 quarters. The position peaked at $1.96M in Q1 2018. 126 funds tracked by Wall St. Rank hold INO as of Q2 2018.

Vident Investment Advisory reported no remaining Inovio Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Vident Investment Advisory sold 33,195 Inovio Pharmaceuticals shares in Q2 2018, an estimated $1.96M.
Vident Investment Advisory first reported a position in Inovio Pharmaceuticals in Q4 2015 and held it in 10 quarters.
Vident Investment Advisory's Inovio Pharmaceuticals position peaked at $1.96M in Q1 2018.
126 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2018.

Based on Vident Investment Advisory's 13F filing for Q2 2018, filed 14 Aug 2018.